BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36528059)

  • 1. Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine.
    Shang Q; Pan C; Zhang X; Yang T; Hu T; Zheng L; Cao S; Feng C; Hu X; Chai X; Wang J; Fang Q
    J Biol Chem; 2023 Jan; 299(1):102798. PubMed ID: 36528059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.
    Hu T; Pan C; Zhang T; Ni M; Wang W; Zhang S; Chen Y; Wang J; Fang Q
    Cancer Gene Ther; 2022 Nov; 29(11):1773-1790. PubMed ID: 35840666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
    Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
    PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
    Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
    Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel protective mechanism of reducing renal cell damage in diabetes: Activation AMPK by AICAR increased NRF2/OGG1 proteins and reduced oxidative DNA damage.
    Habib SL; Yadav A; Kidane D; Weiss RH; Liang S
    Cell Cycle; 2016 Nov; 15(22):3048-3059. PubMed ID: 27611085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
    Rushworth SA; Bowles KM; MacEwan DJ
    Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the PI3K/Akt/Nrf2 Signaling Pathway in Resveratrol-Mediated Reversal of Drug Resistance in HL-60/ADR Cells.
    Li Y; Guo Y; Feng Z; Bergan R; Li B; Qin Y; Zhao L; Zhang Z; Shi M
    Nutr Cancer; 2019; 71(6):1007-1018. PubMed ID: 31032633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
    Owen N; Minko IG; Moellmer SA; Cammann SK; Lloyd RS; McCullough AK
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2.
    Liu P; Ma D; Wang P; Pan C; Fang Q; Wang J
    Cell Death Dis; 2021 Jan; 12(1):20. PubMed ID: 33414469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells.
    Zhang J; Su L; Ye Q; Zhang S; Kung H; Jiang F; Jiang G; Miao J; Zhao B
    Oncotarget; 2017 Jan; 8(5):7625-7636. PubMed ID: 28032588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells.
    Jang JE; Eom JI; Jeung HK; Chung H; Kim YR; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 Apr; 39(1):66. PubMed ID: 32293500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. n-3 Polyunsaturated fatty acids induce acute myeloid leukemia cell death associated with mitochondrial glycolytic switch and Nrf2 pathway activation.
    Picou F; Debeissat C; Bourgeais J; Gallay N; Ferrié E; Foucault A; Ravalet N; Maciejewski A; Vallet N; Ducrocq E; Haddaoui L; Domenech J; Hérault O; Gyan E
    Pharmacol Res; 2018 Oct; 136():45-55. PubMed ID: 30142422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
    Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY
    Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silver nanoparticles down-regulate Nrf2-mediated 8-oxoguanine DNA glycosylase 1 through inactivation of extracellular regulated kinase and protein kinase B in human Chang liver cells.
    Piao MJ; Kim KC; Choi JY; Choi J; Hyun JW
    Toxicol Lett; 2011 Nov; 207(2):143-8. PubMed ID: 21925250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Gu H; Chen C; Hou ZS; He XD; Xie S; Ni J; Qian C; Cheng X; Jiang T; Yang C; Roberts TM; Zheng J; Varner JA; Armstrong SA; Zhao JJ
    Blood; 2024 May; 143(19):1965-1979. PubMed ID: 38271660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
    Long J; Fang WY; Chang L; Gao WH; Shen Y; Jia MY; Zhang YX; Wang Y; Dou HB; Zhang WJ; Zhu J; Liang AB; Li JM; Hu J
    Leukemia; 2017 Dec; 31(12):2761-2770. PubMed ID: 28462918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pterocarpanquinone LQB‑118 compound induces apoptosis of cytarabine‑resistant acute myeloid leukemia cells.
    Hancio T; Mazzoccoli L; Guimarães G; Robaina M; Mendonça BDS; Nestal De Moraes G; Monte-Mor BDCR; Mayumi Gutiyama L; De Carvalho LO; Netto CD; Costa PRR; De Faria FCC; Maia RC
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33786613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
    Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.